

Masaki Yamamoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/984145/publications.pdf>

Version: 2024-02-01

15
papers

174
citations

1307594

7
h-index

1125743

13
g-index

16
all docs

16
docs citations

16
times ranked

210
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pulmonary Enteric Adenocarcinoma. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 253-257.	0.7	5
2	Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial. <i>Thoracic Cancer</i> , 2022, 13, 228-235.	1.9	7
3	Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer. <i>Internal Medicine</i> , 2021, 60, 3593-3598.	0.7	8
4	A functionally improved case of obstructive impairment caused by systemic lupus erythematosus. <i>Breathe</i> , 2021, 17, 200288.	1.3	0
5	The Extent of Honeycombing on Computed Tomography Cannot Predict the Treatment Outcome of Patients with Acute Exacerbations of Interstitial Lung Disease. <i>Canadian Respiratory Journal</i> , 2021, 2021, 1-8.	1.6	0
6	Reproducibility of the T-SPOT.TB test for screening Mycobacterium tuberculosis infection in Japan. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 194-198.	1.7	3
7	MicroRNA miR-200b is a potential biomarker of the expression of PD-L1 in patients with lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 2975-2982.	1.9	12
8	Identification of a novel biomarker based on lymphocyte count, albumin level, and TBAg/PHA ratio for differentiation between active and latent tuberculosis infection in Japan. <i>Tuberculosis</i> , 2020, 125, 101992.	1.9	13
9	Afatinib + bevacizumab combination therapy in EGFR mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial. <i>Thoracic Cancer</i> , 2020, 11, 2125-2129.	1.9	2
10	Identification of Biomarkers for Non-small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor. <i>Anticancer Research</i> , 2020, 40, 3889-3896.	1.1	12
11	Class A CpG oligodeoxynucleotide inhibits IFN- γ -induced signaling and apoptosis in lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 983-992.	1.9	3
12	Clinical significance of Charlson comorbidity index as a prognostic parameter for patients with acute or subacute idiopathic interstitial pneumonias and acute exacerbation of collagen vascular diseases-related interstitial pneumonia. <i>Journal of Thoracic Disease</i> , 2019, 11, 2448-2457.	1.4	25
13	Hepcidin exerts a negative immunological effect in pulmonary tuberculosis without HIV co-infection, prolonging the time to culture-negative. <i>International Journal of Infectious Diseases</i> , 2019, 86, 47-54.	3.3	3
14	Detection of Mycobacterium tuberculosis-derived DNA in circulating cell-free DNA from a patient with disseminated infection using digital PCR. <i>International Journal of Infectious Diseases</i> , 2018, 66, 80-82.	3.3	22
15	Digital PCR assay detection of circulating Mycobacterium tuberculosis DNA in pulmonary tuberculosis patient plasma. <i>Tuberculosis</i> , 2016, 99, 47-53.	1.9	59